

I hereby certify that this correspondence is being electronically filed in the United States Patent and Trademark Office on July 2, 2007.

  
Frank C. Eisenschenk, Ph.D., Patent Attorney

ELECTION UNDER 35 U.S.C. § 121  
Examining Group 1647  
Patent Application  
Docket No. ARS-107  
Serial No. 10/530,104

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Elly Gerald Stoica  
Art Unit : 1647  
Applicants : Mark Ibberson, Christine Power, Achim Frauenschuh  
Serial No. : 10/530,104  
Filed : April 1, 2005  
Conf. No. : 9640  
For : Novel Chemokine-Like Polypeptides

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313

ELECTION UNDER 35 U.S.C. § 121 AND  
SUPPLEMENTAL PRELIMINARY AMENDMENT

Sir:

In response to the written Restriction Requirement dated May 30, 2007 in the above-identified patent application, Applicants hereby elect to prosecute the invention of Group I (claims 42, 44, and 46, in part), with traverse. As the species election, Applicants elect SEQ ID NO: 2 from category A; SEQ ID NO: 1 from category B; and SEQ ID NOS: 17-18 from category C. This species election, as required by the Examiner, possesses internal consistency: SEQ ID NO: 2 corresponds to the 98-amino acid long protein sequence p1754; SEQ ID NO: 1 is the DNA sequence containing the ORF encoding for p1754; and SEQ ID NOS: 17-18 are the primer sequences specific for said ORF. In other words there is a close technical relationship (protein, DNA and primers) among the elected species and examination of the elected invention is respectfully requested. Claims 58-76 and 86-91 read on the elected invention.

Prior to examination, Applicants respectfully request that the subject application be amended as follows: